Blue Label’s share price has grown significantly in the past two years, but portfolio managers are warning there was still significant risk in its plan to list Cell C on the JSE.
Caution from well-known fund manager about Cell C
RELATED ARTICLES
© Newspaper WordPress Theme by TagDiv